https://scholars.lib.ntu.edu.tw/handle/123456789/638444
標題: | Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study | 作者: | Simonelli, M Garralda, E Eskens, F Gil-Martin, M Yen, C-J Obermannova, R Chao, Y Lonardi, S Melichar, B Moreno, V Yu, M-L Bongiovanni, A Calvo, E Rottey, S Machiels, J-P Gonzalez-Martin, A Paz-Ares, L Chang, C-L Mason, W CHIA-CHI LIN Reardon, D A Vieito, M Santoro, A Meng, R Abbadessa, G Menas, F Lee, H Liu, Q Combeau, C Ternes, N Ziti-Ljajic, S Massard, C |
關鍵字: | anti-CD38; anti-PD-L1; atezolizumab; isatuximab; solid tumors | 公開日期: | 十月-2022 | 卷: | 7 | 期: | 5 | 來源出版物: | ESMO open | 摘要: | The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors. This phase I/II study (NCT03637764) assessed the safety and activity of isatuximab plus atezolizumab (Isa + Atezo), an anti-programmed death-ligand 1 (PD-L1) antibody, in patients with immunotherapy-naive solid tumors: epithelial ovarian cancer (EOC), glioblastoma (GBM), hepatocellular carcinoma (HCC), and squamous cell carcinoma of the head and neck (SCCHN). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638444 | ISSN: | 20597029 | DOI: | 10.1016/j.esmoop.2022.100562 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。